4.400
Ensayos registrados
555
Reclutando activamente
21
Especialidades
1
Fuentes de datos
ReclutandoFase 3ClinicalTrials.gov
Effects of Ziltivekimab Versus Placebo on Morbidity and Mortality in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction and Systemic Inflammation
INTERVENTIONALInicio: 8 de may de 2023ID: NCT05636176
ReclutandoFase 3ClinicalTrials.gov
A Multicenter, Randomized, Open-Label, Phase 3 Trial of Trastuzumab Deruxtecan (Enhertu®) Plus Chemotherapy Plus or Minus Pembrolizumab Versus Chemotherapy Plus Trastuzumab Plus or Minus Pembrolizumab as First-Line Treatment in Participants With Unresectable, Locally Advanced or Metastatic HER2-Positive Gastric Or Gastroesophageal Junction (GEJ) Cancer (Destiny-Gastric05)
INTERVENTIONALInicio: 27 de feb de 2025ID: NCT06731478
ReclutandoClinicalTrials.gov
Natural History Study of Synucleinopathies
OBSERVATIONALInicio: 1 de jun de 2011ID: NCT01799915
ReclutandoFase 3ClinicalTrials.gov
A Two-stage Double-blind, Randomized, Placebo-controlled Study to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.
INTERVENTIONALInicio: 24 de nov de 2023ID: NCT05948943
ReclutandoFase 2ClinicalTrials.gov
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Participants With Sjögren's
INTERVENTIONALInicio: 23 de abr de 2025ID: NCT06928142
ReclutandoFase 3ClinicalTrials.gov
A Multicenter Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan in Adult Participants With Primary IgA Nephropathy Who Have Completed Study CLNP023X2203 or CLNP023A2301
INTERVENTIONALInicio: 20 de sept de 2021ID: NCT04557462
Explorar por especialidad
Encuentra ensayos clinicos relevantes para tu area de practica.